GLP1R and obesity disorder: Chemopreventive agents such as aspirin has shown promising effects in reducing the incidence of colorectal cancer among the high-risk population.28 A few recent randomized controlled trials demonstrated that glucagon-like peptide-1 receptor agonists (GLP1RAs) in conjunction with diet and exercise are highly effective in treating obesity.29,30 On the population level, the use of GLP1RAs might prevent 1.3% of all cancers or 3.5% of obesity-related cancers by 2049.31